Showing results (911-920 of 1,024) with videos related to

Sort By:
Pageof 103
Human Mutation|November 19, 2016
Whole-Genome Sequencing of Cytogenetically Balanced Chromosome Translocations Identifies Potentially Pathological Gene Disruptions and Highlights the Importance of Microhomology in the Mechanism of FormationDaniel Nilsson, Maria Pettersson, Peter Gustavsson, et al.
NPJ Vaccines|October 28, 2024
Divergence of variant antibodies following SARS-CoV-2 booster vaccines in myeloma and impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
Biorxiv : the Preprint Server for Biology|September 4, 2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
Research Square|October 4, 2023
Divergence of variant binding/neutralizing antibodies following SARS-CoV-2 booster vaccines in myeloma: Impact of hybrid immunityAlberto Moreno, Kelly Manning, Maryam I Azeem, et al.
Leukemia & Lymphoma|December 1, 2012
Early versus delayed autologous stem cell transplant in patients receiving novel therapies for multiple myelomaNeil C Dunavin, Lai Wei, Patrick Elder, et al.
European Journal of Haematology|April 4, 2019
Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studiesMeletios A Dimopoulos, Jacob P Laubach, Maria Asunción Echeveste Gutierrez, et al.
The Lancet. Haematology|December 5, 2016
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 studyRichard R Furman, Herbert A Eradat, Christine G DiRienzo, et al.
Hematological Oncology|March 2, 2011
Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioningMehdi Hamadani, Michael Craig, Gary S Phillips, et al.
Blood Cancer Journal|November 27, 2019
Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasoneTimothy M Schmidt, Benjamin G Barwick, Nisha Joseph, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 18, 2021
Chromatin Accessibility Identifies Regulatory Elements Predictive of Gene Expression and Disease Outcome in Multiple MyelomaBenjamin G Barwick, Vikas A Gupta, Shannon M Matulis, et al.
Pageof 103